08 Jul 2020
Posted in Pharma
US diagnosed prevalent cases of AL amyloidosis projected to increase by 36.7% over next decade, says GlobalData
The number of diagnosed prevalent cases of AL amyloidosis is expected to increase from 75,033 in 2019 to 89,637 in 2029 at an annual growth rate (AGR) of 1.95% across the seven major markets 7MM*, according to GlobalData, a leading data and analytics company.
Of the 7MM, the US is expected to have the highest number of diagnosed prevalent cases of AL amyloidosis with 23,350 cases in 2019 and increasing at an AGR of 3.67% (2019–2029), followed by Japan (13,361 cases) and Germany (10,415 cases).
GlobalData’s latest report, ‘Amyloidosis – Epidemiology Forecast Report to 2029’, notes that the major drivers for the upward trend of diagnosed prevalent cases of AL amyloidosis may be attributable to better awareness of the disease and/or existence of a national referral centre, as well as improved diagnostic techniques and changing population demographics in the respective markets.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “In all markets, men made up more than 50% of AL amyloidosis cases, although the exact distribution varies by market. Amyloidosis has poor prognosis, and 35% of patients die within six months of diagnosis. Medical doctors caring for patients with AL amyloidosis have been borrowing and modifying therapies used for patients with multiple myeloma with varying degrees of success.
“Unprecedented interest in AL amyloidosis has resulted in improved outcomes for these patients, but more work has to be done in the areas of early diagnosis. Early diagnosis can improve survival and offer better quality of life.”
*7MM: The US, France, Germany, Italy, Spain, the UK and Japan